These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 20812768)

  • 1. Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder.
    Stiefel G; Besag FM
    Drug Saf; 2010 Oct; 33(10):821-42. PubMed ID: 20812768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder: an update.
    Awudu GA; Besag FM
    Drug Saf; 2014 Sep; 37(9):661-76. PubMed ID: 25124483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and Atomoxetine.
    Hennissen L; Bakker MJ; Banaschewski T; Carucci S; Coghill D; Danckaerts M; Dittmann RW; Hollis C; Kovshoff H; McCarthy S; Nagy P; Sonuga-Barke E; Wong IC; Zuddas A; Rosenthal E; Buitelaar JK;
    CNS Drugs; 2017 Mar; 31(3):199-215. PubMed ID: 28236285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular measures in children and adolescents with attention-deficit/hyperactivity disorder who are new users of methylphenidate and atomoxetine.
    Arcieri R; Germinario EA; Bonati M; Masi G; Zuddas A; Vella S; Chiarotti F; Panei P;
    J Child Adolesc Psychopharmacol; 2012 Dec; 22(6):423-431. PubMed ID: 23362511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Priapism associated with the use of stimulant medications and atomoxetine for attention-deficit/hyperactivity disorder in children.
    Eiland LS; Bell EA; Erramouspe J
    Ann Pharmacother; 2014 Oct; 48(10):1350-5. PubMed ID: 24982313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular safety of ADHD medications: rationale for and design of an investigator-initiated observational study.
    Hennessy S; Schelleman H; Daniel GW; Bilker WB; Kimmel SE; Guevara J; Cziraky MJ; Strom BL
    Pharmacoepidemiol Drug Saf; 2010 Sep; 19(9):934-41. PubMed ID: 20623519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of adult ADHD and comorbid disorders.
    Young JL
    CNS Spectr; 2006 Oct; 11(10 Suppl 11):10-2. PubMed ID: 17712918
    [No Abstract]   [Full Text] [Related]  

  • 9. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.
    Garnock-Jones KP; Keating GM
    Paediatr Drugs; 2009; 11(3):203-26. PubMed ID: 19445548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An open study of adjunct OROS-methylphenidate in children who are atomoxetine partial responders: II. Tolerability and pharmacokinetics.
    Hammerness P; Georgiopoulos A; Doyle RL; Utzinger L; Schillinger M; Martelon M; Brodziak K; Biederman J; Wilens TE
    J Child Adolesc Psychopharmacol; 2009 Oct; 19(5):493-9. PubMed ID: 19877973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mortality associated with attention-deficit hyperactivity disorder (ADHD) drug treatment: a retrospective cohort study of children, adolescents and young adults using the general practice research database.
    McCarthy S; Cranswick N; Potts L; Taylor E; Wong IC
    Drug Saf; 2009; 32(11):1089-96. PubMed ID: 19810780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacotherapy of ADHD in adults.
    Wilens TE
    CNS Spectr; 2008 May; 13(5 Suppl 8):11-3. PubMed ID: 18567133
    [No Abstract]   [Full Text] [Related]  

  • 13. Atomoxetine may improve methylphenidates' efficacy in treatment of ADHD?
    Niederhofer H
    Psychiatr Danub; 2009 Sep; 21(3):330. PubMed ID: 19794351
    [No Abstract]   [Full Text] [Related]  

  • 14. Atomoxetine. Attention-deficit/hyperactivity disorder: no better than methylphenidate.
    Prescrire Int; 2010 Feb; 19(105):5-8. PubMed ID: 20455329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medications for attention deficit hyperactivity disorder associated with increased risk of developing glaucoma.
    Darwich R; Etminan M; He B; Eadie BD
    Eye (Lond); 2024 Sep; 38(13):2638-2643. PubMed ID: 38710937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder.
    Martinez-Raga J; Knecht C; Szerman N; Martinez MI
    CNS Drugs; 2013 Jan; 27(1):15-30. PubMed ID: 23160939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological management of attention-deficit hyperactivity disorder.
    Reeves G; Schweitzer J
    Expert Opin Pharmacother; 2004 Jun; 5(6):1313-20. PubMed ID: 15163276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding the risk of using medications for attention deficit hyperactivity disorder with respect to physical growth and cardiovascular function.
    Vitiello B
    Child Adolesc Psychiatr Clin N Am; 2008 Apr; 17(2):459-74, xi. PubMed ID: 18295156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current pharmacotherapy of attention deficit hyperactivity disorder.
    Reddy DS
    Drugs Today (Barc); 2013 Oct; 49(10):647-65. PubMed ID: 24191257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic review of atomoxetine data in childhood and adolescent attention-deficit hyperactivity disorder 2009-2011: focus on clinical efficacy and safety.
    Bushe CJ; Savill NC
    J Psychopharmacol; 2014 Mar; 28(3):204-11. PubMed ID: 23438503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.